Form 4: Teva Executive Mark Sabag Acquires 141,478 RSUs

Teva Pharmaceutical Industries Ltd. Executive Vice President Mark Sabag acquired 141,478 restricted share units, which are subject to time-based vesting until March 3, 2026.

Summary

• Mark Sabag, Executive Vice President, International Markets Commercial for Teva Pharmaceutical Industries Ltd., acquired 141,478 Restricted Share Units (RSUs).
• The transaction date for the acquisition was January 27, 2026.
• These RSUs were received upon the satisfaction of performance criteria for previously granted performance share units.
• Each RSU represents a contingent right to receive one ordinary share or its cash value, at the option of the Human Resources and Compensation Committee.
• The RSUs are subject to time-based vesting and will fully vest on March 3, 2026.
• Following this transaction, Mark Sabag beneficially owns 141,478 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine compensation event. The grant of RSUs upon satisfaction of performance criteria indicates successful executive performance and aligns management incentives with shareholder value, though it's not a direct open-market purchase.

Positives

• The acquisition of 141,478 Restricted Share Units by a key executive, Mark Sabag, aligns management's interests with shareholder value.
• The RSUs were granted upon the satisfaction of performance criteria, indicating successful achievement of prior goals.

Industry Context

StockSavvy.ai notes that the grant of restricted share units to executives is a common practice in the pharmaceutical industry, aligning executive incentives with long-term company performance and shareholder interests. This particular filing reflects a routine compensation event for a senior executive at Teva.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance.

Next Steps

• The 141,478 Restricted Share Units are scheduled to vest on March 3, 2026.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Mark Sabag, Restricted Share Units, RSU, Insider Transaction, Executive Compensation, Form 4, Pharmaceuticals